01 Jan Rifampicin for continuation phase tuberculosis treatment in Uganda: a cost-effectiveness analysis
Posted at 00:00h
in
Authored by: Manabe Yukari C., Hermans Sabine M., Lamorde Mohammed, Castelnuovo Barbara, Mullins C. Daniel, Kuznik Andreas
In: PLOS ONE 7(6), 2012, p.e39187-
http://www.ncbi.nlm.nih.gov/pubmed/22723960